Cargando…

A new paradigm for personalized prophylaxis for patients with severe haemophilia A

AIM: For patients with severe haemophilia A, guidelines recommend prophylactic treatment with FVIII, with dose calculations targeting a predetermined FVIII trough level. However, this pharmacokinetic (PK) approach is suboptimal, with some patients experiencing breakthrough bleeds. We aimed to improv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delavenne, Xavier, Ollier, Edouard, Lienhart, Anne, Dargaud, Yesim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154752/ https://www.ncbi.nlm.nih.gov/pubmed/32100950 http://dx.doi.org/10.1111/hae.13935

Ejemplares similares

Adherence to Prophylaxis in Adolescents and Young Adults with Severe Haemophilia: A Quantitative Study with Patients
por: van Os, Sandra B., et al.
Publicado: (2017)

Adherence to prophylaxis in adolescents and young adults with severe haemophilia A, a qualitative study with patients
por: van Os, S., et al.
Publicado: (2018)

Medication Adherence for Haemophilia Patients: Outcome of Prophylaxis Treatment Intervention
por: Mokhtar, Fadzlin Mohd, et al.
Publicado: (2021)

Haemophilia A: Pharmacoeconomic Review of Prophylaxis Treatment versus On-Demand
por: Unim, Brigid, et al.
Publicado: (2015)

Adherence to prophylaxis in adolescents and young adults with severe haemophilia: a qualitative study with healthcare professionals
por: van Os, S., et al.
Publicado: (2020)

Personalised Prophylaxis in a Child with Haemophilia A and Type 1 Diabetes
por: Cruz, Maria Sol, et al.
Publicado: (2021)

Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature
por: Iorio, Alfonso, et al.
Publicado: (2022)

Clinical Utility of Subcutaneous Factor VIII Replacement Therapies in Hemophilia A: A Review of the Evidence
por: Dargaud, Yesim, et al.
Publicado: (2021)

Social support and resilience in persons with severe haemophilia: An interpretative phenomenological analysis
por: Ratajová, Kateřina, et al.
Publicado: (2020)

PHILEOS (haemoPHILia and ostEoporOSis) Study: protocol of a multicentre prospective case–control study
por: Tardy‐Poncet, Brigitte, et al.
Publicado: (2021)

Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand
por: Oldenburg, J, et al.
Publicado: (2015)

Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial
por: Yang, Renchi, et al.
Publicado: (2019)

Coordinating physiotherapy care for persons with haemophilia
por: Timmer, Merel A., et al.
Publicado: (2021)

Low immunogenicity of emicizumab in persons with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2021)

Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Measurement of joint health in persons with haemophilia: A systematic review of the measurement properties of haemophilia‐specific instruments
por: Gouw, Samantha C., et al.
Publicado: (2018)

Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A
por: Huang, Kun, et al.
Publicado: (2022)

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
por: Dargaud, Yesim, et al.
Publicado: (2021)

Seventy years of haemophilia care: A personal perspective
por: Smit, Cees
Publicado: (2021)

Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia: A comparison between intermediate‐ and high‐dose prophylaxis
por: Versloot, Olav, et al.
Publicado: (2019)

Flap cover in a patient with severe haemophilia type A
por: Manickavachakan, Narender, et al.
Publicado: (2017)

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027
por: Reding, Mark T., et al.
Publicado: (2020)

ACTIVLIM‐Hemo: A new self‐reported, unidimensional and linear measure of activity limitations in persons with haemophilia
por: Lobet, Sébastien, et al.
Publicado: (2022)

A new measure to assess pain in people with haemophilia: The Multidimensional Haemophilia Pain Questionnaire (MHPQ)
por: Paredes, Ana Cristina, et al.
Publicado: (2018)

Hæmophilia
Publicado: (1905)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

Efficacy, safety and bioequivalence of the human‐derived B‐domain‐deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients
por: Xi, Yaming, et al.
Publicado: (2022)

Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain
por: Mareque, María, et al.
Publicado: (2020)

BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
por: Santoro, Cristina, et al.
Publicado: (2020)

Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors
por: Antunes, S V, et al.
Publicado: (2014)

A Comparison of the Incidence Rate for Joint Bleeding and FVIII Consumption between On-Demand versus Prophylaxis Factor VIII Replacement Therapy and the Direct Cost of Prophylaxis Treatment in Severe Haemophilia A Patients
por: Jamal, Munirah, et al.
Publicado: (2023)

Response to “Studies on hemostasis in COVID‐19 deserve careful reporting of the laboratory methods, their significance and their limitation”: Don’t throw the baby out with the bathwater
por: Nougier, Christophe, et al.
Publicado: (2020)

The profile of patients with haemophilia managed at a haemophilia treatment centre in Pretoria, Gauteng
por: Mafisa, Lethukuthula, et al.
Publicado: (2022)

Health-related quality of life of moderate and severe haemophilia patients: Results of the haemophilia-specific quality of life index in Korea
por: Baek, Hee Jo, et al.
Publicado: (2020)

Dengue fever in a patient with severe haemophilia: a case report
por: Wijayaratne, Dilushi, et al.
Publicado: (2015)

The cost of severe haemophilia in Europe: the CHESS study
por: O’Hara, Jamie, et al.
Publicado: (2017)

Osteoporosis management and falls prevention in patients with haemophilia: Review of haemophilia guidelines
por: Petkovic, Madison J., et al.
Publicado: (2022)

Musculoskeletal evaluation in severe haemophilia A patients from Latin America
por: Ozelo, M C, et al.
Publicado: (2013)

A tailored intervention for illness acceptance improves adherence and quality of life in adults with haemophilia using prophylaxis
por: Hoefnagels, Johanna Wilhelmina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qiurh4gnlhle5na44nb1l2q2pr